Trials / Unknown
UnknownNCT01312311
Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer
Phase II Trial of Cisplatin Plus Weekly Docetaxel as the First-line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 51 (estimated)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators will evaluate weekly docetaxel plus 3-weekly cisplatin regimen as the first-line therapy for recurrent of metastatic nasophayngeal cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel, Cisplatin | Docetaxel 35mg/m2 D1 \& D8 Cisplatin 70mg/m2 D1 |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2011-05-01
- First posted
- 2011-03-10
- Last updated
- 2011-03-10
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01312311. Inclusion in this directory is not an endorsement.